Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk: A meta-analysis

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Published studies on the association between the vascular endothelial growth factor (VEGF) gene 936 C/T polymorphism and breast cancer risk are inconclusive, and a meta-analysis is required to verify the association. Nine studies, including a total of 4,973 cases and 5,035 controls, were subjected to meta-analysis. When all eligible subjects were pooled for meta-analysis, the CT + TT genotypes were not associated with a significant decrease in breast cancer risk (odds ratio = 0.87; 95% confidence interval 0.75-1.02; P = 0.087). We also categorized by ethnicity (Caucasian, Asian, or mixed) for subgroup analysis, however, according to this subgroup analysis, we found no significant association between the CT and TT versus CC genotype with breast cancer risk reduction in any of the subgroups. We conclude that the VEGF gene 936 C/T polymorphism does not affect breast cancer risk.

Original languageEnglish
Pages (from-to)849-853
Number of pages5
JournalBreast Cancer Research and Treatment
Volume125
Issue number3
DOIs
Publication statusPublished - 2011 Feb 1

Fingerprint

Vascular Endothelial Growth Factor A
Meta-Analysis
Breast Neoplasms
Genes
Odds Ratio
Genotype
Risk Reduction Behavior
Confidence Intervals

Keywords

  • 936 C/T polymorphism
  • Breast cancer risk
  • Meta-analysis
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{2ad74f8103fc4cb79c07e73eeca6b6e1,
title = "Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk: A meta-analysis",
abstract = "Published studies on the association between the vascular endothelial growth factor (VEGF) gene 936 C/T polymorphism and breast cancer risk are inconclusive, and a meta-analysis is required to verify the association. Nine studies, including a total of 4,973 cases and 5,035 controls, were subjected to meta-analysis. When all eligible subjects were pooled for meta-analysis, the CT + TT genotypes were not associated with a significant decrease in breast cancer risk (odds ratio = 0.87; 95{\%} confidence interval 0.75-1.02; P = 0.087). We also categorized by ethnicity (Caucasian, Asian, or mixed) for subgroup analysis, however, according to this subgroup analysis, we found no significant association between the CT and TT versus CC genotype with breast cancer risk reduction in any of the subgroups. We conclude that the VEGF gene 936 C/T polymorphism does not affect breast cancer risk.",
keywords = "936 C/T polymorphism, Breast cancer risk, Meta-analysis, VEGF",
author = "Dae-Sik Yang and Park, {Kyong Hwa} and Woo, {Ok Hee} and Woo, {Sang- Uk} and Aeree Kim and Lee, {Eun Sook} and Lee, {Jae Bok} and Kim, {Yeul Hong} and Kim, {Jun Suk} and Seo, {Jae Hong}",
year = "2011",
month = "2",
day = "1",
doi = "10.1007/s10549-010-1070-1",
language = "English",
volume = "125",
pages = "849--853",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk

T2 - A meta-analysis

AU - Yang, Dae-Sik

AU - Park, Kyong Hwa

AU - Woo, Ok Hee

AU - Woo, Sang- Uk

AU - Kim, Aeree

AU - Lee, Eun Sook

AU - Lee, Jae Bok

AU - Kim, Yeul Hong

AU - Kim, Jun Suk

AU - Seo, Jae Hong

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Published studies on the association between the vascular endothelial growth factor (VEGF) gene 936 C/T polymorphism and breast cancer risk are inconclusive, and a meta-analysis is required to verify the association. Nine studies, including a total of 4,973 cases and 5,035 controls, were subjected to meta-analysis. When all eligible subjects were pooled for meta-analysis, the CT + TT genotypes were not associated with a significant decrease in breast cancer risk (odds ratio = 0.87; 95% confidence interval 0.75-1.02; P = 0.087). We also categorized by ethnicity (Caucasian, Asian, or mixed) for subgroup analysis, however, according to this subgroup analysis, we found no significant association between the CT and TT versus CC genotype with breast cancer risk reduction in any of the subgroups. We conclude that the VEGF gene 936 C/T polymorphism does not affect breast cancer risk.

AB - Published studies on the association between the vascular endothelial growth factor (VEGF) gene 936 C/T polymorphism and breast cancer risk are inconclusive, and a meta-analysis is required to verify the association. Nine studies, including a total of 4,973 cases and 5,035 controls, were subjected to meta-analysis. When all eligible subjects were pooled for meta-analysis, the CT + TT genotypes were not associated with a significant decrease in breast cancer risk (odds ratio = 0.87; 95% confidence interval 0.75-1.02; P = 0.087). We also categorized by ethnicity (Caucasian, Asian, or mixed) for subgroup analysis, however, according to this subgroup analysis, we found no significant association between the CT and TT versus CC genotype with breast cancer risk reduction in any of the subgroups. We conclude that the VEGF gene 936 C/T polymorphism does not affect breast cancer risk.

KW - 936 C/T polymorphism

KW - Breast cancer risk

KW - Meta-analysis

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=79151485536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79151485536&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-1070-1

DO - 10.1007/s10549-010-1070-1

M3 - Article

C2 - 20652396

AN - SCOPUS:79151485536

VL - 125

SP - 849

EP - 853

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -